In MPN patients, elevated levels of hs-CRP (>3 mg/L) are associated with an increased risk of thrombotic events, whereas higher levels of PTX-3 (>4.5 ng/mL) are linked to a reduced risk of thrombosis. Here, PTX3 is linked to myeloproliferative neoplasm.